ATE373711T1 - Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten - Google Patents

Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten

Info

Publication number
ATE373711T1
ATE373711T1 AT01913024T AT01913024T ATE373711T1 AT E373711 T1 ATE373711 T1 AT E373711T1 AT 01913024 T AT01913024 T AT 01913024T AT 01913024 T AT01913024 T AT 01913024T AT E373711 T1 ATE373711 T1 AT E373711T1
Authority
AT
Austria
Prior art keywords
tissue
highly expressed
cancer
expressed
various types
Prior art date
Application number
AT01913024T
Other languages
English (en)
Inventor
Arthur Raitano
Daniel Afar
Gazelle Rastegar
Steve Mitchell
Rene Hubert
Pia Challita-Eid
Mary Faris
Aya Jakobovits
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of ATE373711T1 publication Critical patent/ATE373711T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01913024T 2000-02-24 2001-02-26 Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten ATE373711T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18455800P 2000-02-24 2000-02-24
US21885600P 2000-07-13 2000-07-13

Publications (1)

Publication Number Publication Date
ATE373711T1 true ATE373711T1 (de) 2007-10-15

Family

ID=26880247

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01913024T ATE373711T1 (de) 2000-02-24 2001-02-26 Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten

Country Status (7)

Country Link
EP (1) EP1257644B1 (de)
AT (1) ATE373711T1 (de)
AU (2) AU2001241742B8 (de)
CA (1) CA2400443A1 (de)
DE (1) DE60130541T2 (de)
IL (2) IL151335A0 (de)
WO (1) WO2001062925A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212343A4 (de) * 1999-09-03 2004-11-03 Human Genome Sciences Inc 52 menschliche sekretierte proteine
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
WO2003020954A2 (en) 2001-08-31 2003-03-13 Agensys, Inc. 205p1b5 in treatment and detection of cancer
EP3641804A1 (de) * 2017-06-22 2020-04-29 Institut Gustave Roussy Humanes endogenes retrovirales protein
US20230287067A1 (en) * 2020-01-21 2023-09-14 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Human immunogenic epitopes of hemo and hhla2 human endogenous retroviruses (hervs)
DE102020125457A1 (de) * 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
AU2024296108A1 (en) * 2023-07-20 2026-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Identification of sequence variants of the ervmer34-1 sequence family and use in anti-cancer therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519666A (ja) * 1997-04-10 2001-10-23 ジェネティックス・インスチチュート・インコーポレーテッド 分泌発現配列タグ(sESTs)
EP1074617A3 (de) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers für Synthese von ganzen-Länge cDNS und deren Anwendung
EP1212343A4 (de) * 1999-09-03 2004-11-03 Human Genome Sciences Inc 52 menschliche sekretierte proteine

Also Published As

Publication number Publication date
AU2001241742B2 (en) 2006-04-06
EP1257644B1 (de) 2007-09-19
AU2001241742B8 (en) 2006-05-11
DE60130541T2 (de) 2008-06-19
WO2001062925A3 (en) 2002-03-28
IL151335A (en) 2009-09-01
AU4174201A (en) 2001-09-03
WO2001062925A2 (en) 2001-08-30
IL151335A0 (en) 2003-04-10
CA2400443A1 (en) 2001-08-30
EP1257644A2 (de) 2002-11-20
DE60130541D1 (de) 2007-10-31

Similar Documents

Publication Publication Date Title
PT1200590E (pt) Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
AU2001287639A1 (en) Trp8, trp9 and trp10, markers for cancer
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
ATE478952T1 (de) 36p6d5: ausgeschiedenes tumorprotein
WO2002016413A8 (en) Cripto tumour polypeptide
CY1109125T1 (el) Θεραπευτικα και διαγνωστικα anti-hsp 70 αντισωματα
WO2002088750A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
DK2182064T3 (da) Gen udtrykt i prostatakræft
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
WO2002081642A3 (en) Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
DE60130541D1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
AU2002251754A1 (en) Therapeutic modulation of the tumor inflammatory response
WO2001079557A3 (en) Gtp-binding protein useful in treatment and detection of cancer
AU2001233912A1 (en) Diagnosis of breast cancer using bcmp-81 as marker
WO2001059110A3 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
IL147952A0 (en) G protein-coupled receptor up-regulated in prostate cancer and uses thereof
WO2001059115A3 (en) 83p5g4: a tissue specific protein highly expressed in prostate cancer
WO2003042700A3 (en) Breast cancer associated polypeptide
WO2003020954A3 (en) 205p1b5 in treatment and detection of cancer
WO2001090157A8 (en) 98p7c3: homeodomain protein highly expressed in various cancers
WO2004078123A3 (en) Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
AU2003247704A8 (en) Methods and compositions for diagnosing hepatocellular carcinoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties